• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BRCA1 Gene Record

  • Summary
  • Interactions
  • Claims
  • BRCA1 672 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    672
    BRCA1, DNA REPAIR ASSOCIATED
    BRCA1
    BRCAI
    BRCC1
    BROVCA1
    FANCS
    IRIS
    PNCA4
    PPP1R53
    PSCP
    RNF53
    113705
    1100
    ENSG00000012048
    OTTHUMG00000157426
    PA25411
    P38398
    6
    BRCA1 DNA REPAIR ASSOCIATED

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (12 More Sources)

    Gene Categories: Category Details

    TUMOR SUPPRESSOR
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    ENZYME

    Publications:

    Tassone et al., 2003, BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells., Br. J. Cancer
    Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.
    Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
    LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.
    Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.
    O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
    Golan T et al., 2014, Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers., Br J Cancer
    Mo et al., 2016, mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer., Clin. Cancer Res.
    Drost et al., 2011, BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance., Cancer Cell
    Drost et al., 2016, BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1., J. Clin. Invest.
    Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.
    Kaufman et al., 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation., J. Clin. Oncol.
    Tutt et al., 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial., Lancet
    2017 Aug 9, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N Engl J Med
    Gelmon et al., 2011, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study., Lancet Oncol.
    Liu et al., 2014, Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study., Lancet Oncol.
    Fong et al., 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers., N. Engl. J. Med.
    Robson et al., 2017, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N. Engl. J. Med.
    Goff, 2013, Advanced ovarian cancer: what should be the standard of care?, J Gynecol Oncol
    Golan T et al., 2019, Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer., N Engl J Med
    Marshall CH et al., 2019, Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations., Eur Urol
    Moore K et al., 2018, Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer., N Engl J Med
    Ledermann J et al., 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial., Lancet Oncol
    Caulfield SE et al., 2019, Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a <i>BRCA</i>1/2 Mutation., J Adv Pract Oncol
    Wang et al., 2016, RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance., J. Clin. Invest.
    Drew et al., 2016, Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer., Br. J. Cancer
    Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
    Kondrashova O et al., 2017 Sep, Secondary Somatic Mutations Restoring &lt;i&gt;RAD51C&lt;/i&gt; and &lt;i&gt;RAD51D&lt;/i&gt; Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma., Cancer Discov
    Swisher et al., 2017, Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial., Lancet Oncol.
    Quinn et al., 2003, BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis., Cancer Res.
    Narod SA et al., 2000, Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group., Lancet
    Pierce LJ et al., 2006, Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer., J Clin Oncol
    Gronwald J et al., 2006, Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update., Int J Cancer
    Metcalfe K et al., 2004, Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers., J Clin Oncol
    Jones et al., 2005, Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer., Oncogene
    Leijen et al., 2016, Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months., J. Clin. Oncol.
    Sandhu et al., 2013, The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial., Lancet Oncol.
    Mirza et al., 2016, Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer., N. Engl. J. Med.
    Nolan et al., 2016, RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers., Nat. Med.
    Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.
    Wiltshire et al., 2007, BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven., Mol. Pharmacol.
    Xing et al., 2006, A mouse model for the molecular characterization of brca1-associated ovarian carcinoma., Cancer Res.
    Isakoff et al., 2015, TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer., J. Clin. Oncol.
    Vollebergh et al., 2011, An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients., Ann. Oncol.
    Xu et al., 2017, CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours., Nat Commun
    McGonigle et al., 2015, E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling., Oncotarget
    de Bono et al., 2017, Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers., Cancer Discov
    Shen et al., 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency., Clin. Cancer Res.
    Srinivas et al., 2004, Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells., Mol. Carcinog.
  • GAMMA-FAGARINE   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • 7-HYDROXYFLAVONE   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • 2-PHENYLQUINOLINE   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1709259   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • GLABRIDIN   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TIAPROFENIC ACID   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL12658   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1404865   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL273891   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DENOSUMAB   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Emerging
    Approval Status Clinical Study
    Response Type not applicable

    PMIDs:
    27322743


    Sources:
    JAX-CKB

  • CHEMBL1481721   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1333798   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • WISTIN   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1320798   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL446567   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OLAPARIB   BRCA1

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    26546619 22172724 27454287 25193512 25366685 20609467 28792849 21862407 25218906 19553641 28578601 23346317 31157963 30797618 30345884 24882434 31538027


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

  • VELIPARIB   BRCA1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Veliparib + Carboplatin
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    25589624 26801247 26842236 25824335 29338080


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • QUARFLOXIN   BRCA1

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28211448


    Sources:
    CIViC

  • IROFULVEN   BRCA1

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17229870


    Sources:
    NCI

  • NIRAPARIB   BRCA1

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian cancer
    Response Type sensitive
    Approval Status FDA approved

    PMIDs:
    23810788 27717299


    Sources:
    ClearityFoundationBiomarkers JAX-CKB PharmGKB OncoKB

  • TALAZOPARIB   BRCA1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26546619 28242752 23881923


    Sources:
    JAX-CKB CIViC PharmGKB OncoKB

  • RIBOFLAVIN   BRCA1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL600315   BRCA1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1078244   BRCA1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • 2X-121   BRCA1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26513298


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • CHEMBL589207   BRCA1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SEMUSTINE   BRCA1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL153505   BRCA1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1308677   BRCA1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • THUNBERGINOL E   BRCA1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL66279   BRCA1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL593254   BRCA1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CALYCOSIN   BRCA1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHRYSIN DIMETHYL ETHER   BRCA1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL316796   BRCA1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ILEPCIMIDE   BRCA1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAIDZIN   BRCA1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAMIPARIB   BRCA1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • CHEMBL588525   BRCA1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RUCAPARIB   BRCA1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian carcinoma
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    27454289 27002934 26779812 28588062 27908594


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

  • CHEMBL1214407   BRCA1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL588683   BRCA1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DIMETHYL YELLOW   BRCA1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1405979   BRCA1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • HARMALOL   BRCA1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VITAMIN B2   BRCA1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • 6-HYDROXYFLAVONE   BRCA1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL515763   BRCA1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1998001   BRCA1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL587620   BRCA1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL452954   BRCA1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • 7-HYDROXY ISOFLAVONE   BRCA1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NILE RED   BRCA1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ONONIN   BRCA1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL546649   BRCA1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1420181   BRCA1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1574420   BRCA1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TANSHINONE IIA SULFONATE   BRCA1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • THIABENDAZOLE   BRCA1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHLORAMBUCIL   BRCA1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25193512


    Sources:
    JAX-CKB

  • CHEMBL546865   BRCA1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL581910   BRCA1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PHENAMIL METHANESULFONATE   BRCA1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL581929   BRCA1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VINORELBINE   BRCA1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase I
    Response Type sensitive

    PMIDs:
    26801247 14559807


    Sources:
    JAX-CKB NCI

  • PIFEXOLE   BRCA1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL114544   BRCA1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL484663   BRCA1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAMOXIFEN   BRCA1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11130383 16636335 16331614 15197194 15750629


    Sources:
    NCI PharmGKB

  • BERZOSERTIB   BRCA1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type predicted – sensitive
    Indication/Tumor Type triple-receptor negative breast cancer
    combination therapy Cisplatin + VX-970

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • BLEOMYCIN   BRCA1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14559807


    Sources:
    NCI

  • CHEMBL323356   BRCA1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PIPERINE   BRCA1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBOPLATIN   BRCA1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Carboplatin + VX-970
    Indication/Tumor Type ovarian cancer
    Response Type sensitive

    PMIDs:
    25847936 27998224 25824335 21135055


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • OXALIPLATIN   BRCA1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25072261


    Sources:
    ClearityFoundationBiomarkers CIViC

  • EMODIN   BRCA1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14694444


    Sources:
    NCI

  • CISPLATIN   BRCA1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    16982732 27454289 26801247 25193512 29338080 25072261 25847936


    Sources:
    ClearityFoundationBiomarkers JAX-CKB NCI CIViC

  • ADAVOSERTIB   BRCA1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type predicted – sensitive

    PMIDs:
    27998224


    Sources:
    JAX-CKB

  • QUINALIZARIN   BRCA1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ACRIFLAVINE   BRCA1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEMOZOLOMIDE   BRCA1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Talazoparib + Temozolomide
    Indication/Tumor Type ovarian cancer
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • EVEROLIMUS   BRCA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    combination therapy Olaparib + Everolimus
    Indication/Tumor Type triple-receptor negative breast cancer

    PMIDs:
    26546619


    Sources:
    JAX-CKB

  • GEMCITABINE   BRCA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12684687 29338080


    Sources:
    NCI CIViC

  • MITOXANTRONE   BRCA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12684687


    Sources:
    NCI

  • PURPURIN   BRCA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CEDIRANIB   BRCA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25218906


    Sources:
    CIViC

  • DEPHOSTATIN   BRCA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • APIGENIN   BRCA1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IRINOTECAN   BRCA1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Irinotecan + Veliparib
    Indication/Tumor Type ovarian cancer
    Response Type predicted – sensitive

    PMIDs:
    26842236


    Sources:
    JAX-CKB

  • AURINTRICARBOXYLIC ACID   BRCA1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PACLITAXEL   BRCA1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Carboplatin + Paclitaxel + Veliparib
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive

    PMIDs:
    12684687


    Sources:
    JAX-CKB NCI

  • DAUNORUBICIN HYDROCHLORIDE   BRCA1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOXORUBICIN HYDROCHLORIDE   BRCA1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CYCLOPHOSPHAMIDE   BRCA1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Veliparib + Cyclophosphamide
    Indication/Tumor Type ovarian cancer
    Response Type no benefit

    PMIDs:
    25589624


    Sources:
    JAX-CKB

  • RESVERATROL   BRCA1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOXORUBICIN   BRCA1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12698198


    Sources:
    NCI

  • DIPYRIDAMOLE   BRCA1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Ensembl: ENSG00000012048

    • Version: 101_38

    Alternate Names:
    BRCA1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • JAX-CKB: BRCA1

    • Version: 27-September-2017

    Alternate Names:
    672 CKB Entrez Id
    BRCA1 CKB Gene Synonym
    BRCAI CKB Gene Synonym

    Gene Info:

    Publications:
    Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.
    Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
    Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.

  • PharmGKB: BRCA1

    • Version: 18-August-2020

    Alternate Names:
    PA25411 PharmGKB ID

    Gene Info:

    Publications:
    Narod SA et al., 2000, Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group., Lancet
    Metcalfe K et al., 2004, Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers., J Clin Oncol
    Gronwald J et al., 2006, Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update., Int J Cancer

  • CIViC: BRCA1

    • Version: 14-September-2020

    Alternate Names:
    672 Entrez Gene ID
    6 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE, CLINICALLY ACTIONABLE

    Publications:
    Xu et al., 2017, CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours., Nat Commun
    Golan T et al., 2019, Maintenance Olaparib for Germline &lt;i&gt;BRCA&lt;/i&gt;-Mutated Metastatic Pancreatic Cancer., N Engl J Med
    Goff, 2013, Advanced ovarian cancer: what should be the standard of care?, J Gynecol Oncol

  • NCI: BRCA1

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Tassone et al., 2003, BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells., Br. J. Cancer
    Jones et al., 2005, Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer., Oncogene
    Quinn et al., 2003, BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis., Cancer Res.

  • HingoraniCasas: ENSG00000012048

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000012048 Gene Symbol
    BRCA1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • OncoKB: BRCA1

    • Version: 23-July-2020

    Alternate Names:
    672 OncoKB Entrez Id
    RNF53 OncoKB Gene Synonym
    IRIS OncoKB Gene Synonym

    Gene Info:

    Publications:

  • HumanProteinAtlas: BRCA1

    • Version: 19.3

    Alternate Names:
    ENSG00000012048 Ensembl Gene ID
    BRCC1 Human Protein Atlas Gene Synonym
    FANCS Human Protein Atlas Gene Synonym

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • GO: BRCA1

    • Version: 01-February-2022

    Alternate Names:
    RNF53 GO Gene Synonym

    Gene Info:

    Gene Categories:
    TUMOR SUPPRESSOR

    Publications:

  • Tempus: BRCA1

    • Version: 11-November-2018

    Alternate Names:
    BRCA1 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • MskImpact: BRCA1

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationBiomarkers: BRCA1

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • DTC: BRCA1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: BRCA1

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: BRCA1

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Oncomine: BRCA1

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21